Skip to main content

Table 1 Relationship of different variables in study population with IL17 expression

From: Immunohistochemical expression of interleukin-17 and hormonal receptors in benign and malignant breast lesions

 IL17 expressionTotal (n = 137)P value
No expressionMildModerateStrong
Age group
 Not more than 201 (100%)0 (0.0%)0 (0.0%)0 (0.0%)1 (0.7%)0.065
 21 to 40 years13 (43.3%)5 (16.7%)7 (23.3%)5 (16.7%)30 (21.9%)
 41 to 60 years38 (44.7%)13 (15.3%)9 (10.6%)25 (29.4%)85 (62.0%)
 Above 60 years5 (29.4%)2 (11.8%)8 (47.1%)2 (11.8%)17 (12.4%)
Tumor type
 Benign23 (57.5%)0 (0.0%)10 (25.0%)7 (17.5%)40 (29.2%)0.002
 Malignant34 (34.1%)22 (22.7%)15 (15.5%)26 (26.8%)97 (70.8%)
Diagnosis of breast lesion
 IDC30 (34.5%)19 (21.8%)13 (14.9%)25 (28.7%)87 (63.5%)0.035
 DE7 (63.6%)0 (0.0%)4 (36.4%)0 (0.0%)11 (8.0%)
 FA12 (57.1%)0 (0.0%)6 (28.6%)3 (14.3%)21 (15.3%)
 FC2 (50.0%)0 (0.0%)0 (0.0%)2 (50.0%)4 (2.9%)
 IDCS2 (66.7%)1 (33.3%)0 (0.0%)0 (0.0%)3 (2.2%)
 ILC2 (28.6%)2 (28.6%)2 (28.6%)1 (14.3%)7 (5.1%)
 Lipoma2 (100%)0 (0.0%)0 (0.0%)0 (0.0%)2 (1.5%)
 PTS0 (0.0%)0 (0.0%)0 (0.0%)2 (100%)2 (1.5%)
ER
 Mild10 (37.0%)7 (25.9%)3 (11.1%)7 (25.9%)27 (19.7%)0.678
 Moderate3 (21.4%)4 (28.6%)4 (28.6%)3 (21.4%)14 (10.2%)
 Strong5 (29.4%)5 (29.4%)1 (5.9%)6 (35.3%)17 (12.4%)
 No expression16 (41.0%)6 (15.4%)7 (17.9%)10 (25.6%)39 (28.5%)
PR
 Mild9 (37.5%)6 (25.0%)3 (12.5%)6 (25.0%)24 (17.5%)0.623
 Moderate3 (30.0%)3 (30.0%)1 (10.0%)3 (30.0%)10 (7.3%)
 Strong1 (8.3%)3 (25.0%)2 (16.7%)6 (50.0%)12 (8.8%)
 No expression21 (41.2%)10 (19.6%)9 (17.6%)11 (21.6%)51 (37.2%)
HER2
 Mild7 (35.0%)7 (35.0%)0 (0.0%)6 (30.0%)20 (14.6%)0.361
 Moderate7 (46.7%)2 (13.3%)3 (20.0%)3 (20.0%)15 (10.9%)
 Strong8 (33.3%)3 (12.5%)4 (16.7%)9 (37.5%)24 (17.5%)
 No expression12 (31.6%)10 (26.3%)8 (21.1%)8 (21.1%)38 (27.7%)
  1. ER estrogen receptor, PR progesterone receptor, HER2 Human epidermal receptor-2